A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts

Inclusion Criteria

• •Male \>/= 18 years of age
• •Histologically or cytologically confirmed adenocarcinoma of the prostate.
• •Document current evidence of metastatic castration-resistant prostate cancer (mCRPC), where metastatic status is defined as having documented metastatic lesion(s) on either bone scan or CT/MRI scan.
• •Patients who have received at least three prior intended life-prolonging therapies for metastatic disease.
• •Eastern Collaborative Oncology Group (ECOG) Performance Status of 0-1.
• •Progressive disease, either measurable on physical examination or imaging by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or PCWG3 or by informative tumor marker(s).
• •Adequate organ function based on laboratory values.
• •If there is a known history of brain metastases, either treated or untreated, the disease must be stable.